ERBB2 and breast carcinoma: Establishment of the B7-H1/PD-L1 CTC analysis was performed for the first time by Mazel et al. showing that PD-L1 is frequently expressed on metastatic cells circulating in the blood of hormone receptor-positive, HER2-negative breast cancer patients [9].